ea0031p42 | Clinical biochemistry | SFEBES2013
Wilkinson Ian
, Cawley Pippa
, Bielohuby Maximilian
, Sayers Jon
, Artymiuk Peter
, Bidlingmaier Martin
, Ross Richard
Background: The development of recombinant biologics has had a major impact on many diseases. However, most biologics are rapidly cleared from the body and therefore require frequent injection regimens. There is therefore a need for technologies that allow the half-lives of these molecules to be extended in a predictable manner.HypothesisIncreasing numbers of N-linked glycosylation motifs between two GH molecules leads to gradually...